Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels.

Young children with XLH experience sustained growth on long-term burosumab treatment, although without normal plasma phosphate concentration in many. Consideration should be made to changing burosumab dosing recommendations to target normalisation of alkaline phosphatase, as opposed to plasma phosphate concentration.